• Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Biogen Idec Inc

+ Add to Watchlist

BIIB:US

290.540 USD 0.940 0.32%

As of 20:10:00 ET on 04/17/2014.

Snapshot for Biogen Idec Inc (BIIB)

Open: 291.000 Day's Range: 289.760 - 296.000 Volume: 1,283,744
Previous Close: 291.480 52wk Range: 194.660 - 358.890 1-Yr Rtn: +42.93%

Stock Chart for BIIB

No chart data available.
  • BIIB:US 290.540
  • 1D
  • 1M
  • 1Y
291.480
Interactive BIIB Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for BIIB

Current P/E Ratio (ttm) 37.1515
Estimated P/E(12/2014) 25.6457
Relative P/E vs. SPX 2.1603
Earnings Per Share (USD) (ttm) 7.8204
Est. EPS (USD) (12/2014) 11.3290
Est. PEG Ratio 1.2976
Market Cap (M USD) 68,681.89
Shares Outstanding (M) 236.39
30 Day Average Volume 2,070,292
Price/Book (mrq) 7.9614
Price/Sale (ttm) 9.9289
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 04/23/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for BIIB

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for BIIB

Biogen Idec Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company's products address diseases such as multiple sclerosis, non-Hodgkin's lymphoma, rheumatoid arthritis, Crohn's disease, and psoriasis.

George A ScangosChief Executive OfficerSusan H AlexanderExec VP/Chief Legal Ofcr/Secy
Paul J ClancyExec VP:Finance/CFOStephen H Holtzman "Steve"Exec VP:Corporate Development
More Company Profile & Key Executives for BIIB

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil